Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

CARA - Cara Therapeutics

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by StockJock-e, Jul 25, 2016.

  1. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment acute postoperative pain in adult patients, as well as completed Phase II clinical trials for the treatment of uremic pruritus disease. The company is also developing Oral CR845, which is in Phase IIa clinical trials for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial stage for treating neuropathic and inflammatory pain. It has licensing agreements with Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize products containing CR845 in South Korea; and Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Shelton, Connecticut.

    [​IMG]
     
    Ciao (Sheppy) likes this.
  2. Ciao (Sheppy)

    Ciao (Sheppy) Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    4,064
    Likes Received:
    616
    Gil you are coping all my stocks :mad::mad: :D

    glad you opened a cara thread ... I got few that I wanted to open but didn't had much time
    then I thought if I do no one will look a scalper thread :(;):D
     
  3. Ciao (Sheppy)

    Ciao (Sheppy) Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    4,064
    Likes Received:
    616
    today hod $7 (so far:rolleyes: )
     
  4. LloydWCoutee

    LloydWCoutee Active Member

    Joined:
    May 4, 2016
    Messages:
    725
    Likes Received:
    58
    i don't expect this to make new high today, but guess well see
     
  5. Ciao (Sheppy)

    Ciao (Sheppy) Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    4,064
    Likes Received:
    616
    I agree with you ...( but I never say never... I look at it with a "scalp eye" ;)):D
     
  6. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    Today its CARA's turn to shine!
     
  7. Tiptopptrader

    Tiptopptrader Well-Known Member

    Joined:
    Mar 31, 2016
    Messages:
    5,036
    Likes Received:
    1,150
    Coverage initiated on Cara Therapeutics by H.C. Wainwright with a Buy

    upload_2016-10-13_6-45-26.png
     
  8. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    First decent bounce today since the sell off from $10
     
  9. LloydWCoutee

    LloydWCoutee Active Member

    Joined:
    May 4, 2016
    Messages:
    725
    Likes Received:
    58
    CARA 1/3 of average daily volume for 3 months.. .nice
     
  10. Tiptopptrader

    Tiptopptrader Well-Known Member

    Joined:
    Mar 31, 2016
    Messages:
    5,036
    Likes Received:
    1,150
    CARA missed on earnings but not missing the market rally

    upload_2016-11-7_8-6-33.png
     
  11. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    Some serious buyers here, looks like a trip back to double digits in the works
     
  12. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    Up and over resistance!
     
  13. bigbear0083

    bigbear0083 Content Manager
    Staff Member

    Joined:
    Mar 29, 2016
    Messages:
    16,391
    Likes Received:
    5,323
    up another +20% today

    [​IMG]
     
  14. Tiptopptrader

    Tiptopptrader Well-Known Member

    Joined:
    Mar 31, 2016
    Messages:
    5,036
    Likes Received:
    1,150
    Off the highs but still looking strong

    upload_2016-11-16_11-5-38.png
     
  15. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    705
    Likes Received:
    61
    [​IMG]
    The long and short trends are positive! Comparing the yearly performance of all stocks, we notice that CARA is one of the better-performing stocks in the market, outperforming 97% of all stocks.
     
    StockJock-e likes this.
  16. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    CARA -9% premarket but lots of bulls like this dip.
     
  17. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    We got some action here!
     
  18. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    20.65, nice move so far!
     
  19. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,497
    Likes Received:
    1,714
    Cara Therapeutics Inc. shares CARA, +12.95% surged 16% in premarket trade Tuesday, after the biotech reported positive results in a trial of a treatment for uremic pruritus, or UP. UP is a debilitating systemic itch condition that affects patients with chronic kidney disease, the company said in a statement. There are currently no approved therapies for the condition in the U.S. The results from Part A of a phase 2 to 3 trial of I.V. CR845 met primary and secondary endpoints for efficacy, said Cara. The company is planning to meet with the U.S. Food and Drug Administration to finalize the design of Part B of the study and to start recruiting patients later this year. CR845 is being developed for the treatment of acute and chronic pain as well as UP. Cara shares have gained 95% in the year so far, while the S&P 500 SPX, -0.10% has gained 4.6%.

    http://www.marketwatch.com/story/ca...e-results-in-trial-of-up-treatment-2017-03-28
     
    hipchack likes this.

Share This Page